Loading market dashboard
GRAIL, Inc.
GRALHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK--(BUSINESS WIRE)---- $GRAL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recover.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Grail class action lawsuit seeks to represent purchasers or acquirers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). Captioned Robbins v.
[url="]Robbins LLP[/url] informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ:
SAN DIEGO--(BUSINESS WIRE)---- $GRAL #Grail--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. Grail, Inc. describes itself as a commercial stage healthcare company with a focus on early cancer detection through screening methodology.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: R.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their Options
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ: GRAL) between May 13, 2025, and February 19, 2026, inclusive. You are hereby notified that the class action lawsuit William Robbins v.
Investors remain hopeful that the Galleri test can gain FDA approval and medical insurance coverage.
The Galleri test failed its primary endpoint in a landmark trial, but that doesn't mean it doesn't have a big future.
The cancer test maker could still have a bright future.
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
The market was disappointed by the more detailed data on a landmark trial for the company's multi-cancer early detection (MCED) test.
Stocks are trading mixed as surging oil prices and Iran updates overshadow an earlier chip stock rally
GRAIL NASDAQ: GRAL said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its largest randomized trial was not met.
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With R
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers Detected by the Galleri Test Were in Stages I-III MENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from the analysis of the full 35,878 cohort of its registrational PATHFINDER 2 study are being presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting[1].
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri ® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, Respectively Galleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25% Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of Care GRAIL to Host Analyst Call From 2026 ASCO Annual Meeting MENLO PARK, Calif., May 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced detailed clinical utility, performance and safety results from its landmark NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting1.
MENLO PARK, Calif., May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 34,350 shares of GRAIL's common stock to 56 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
MENLO PARK, Calif., May 26, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m.
Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon.
MENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m.
GRAIL NASDAQ: GRAL said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company's CFO, at a Bank of America event.
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo Geneva and its Chairman, billionaire engineer Zaya Younan, announce a breakthrough that transcends luxury: the Patented Refrigerated Ashtray.
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access Nationwide New Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting MENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.
MENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12 at 8:40 a.m.
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026.
Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri ® Clinical Development Program MENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2, 2026.
Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, April 15, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.
Carnegie Investment Counsel lowered its stake in GRAIL, Inc. (NASDAQ: GRAL) by 13.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 213,050 shares of the company's stock after selling 32,265 shares during the period. Carnegie Investment Counsel
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 45,806 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares in the company, valued at
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) President Joshua Ofman sold 61,665 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the completion of the transaction, the president directly owned 371,216 shares of the company's
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Robert Ragusa sold 123,502 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares in the
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.
GRAIL, Inc. (NASDAQ: GRAL) shares are up during Wednesday's premarket session.
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of Care MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Epic to bring the Galleri® multi-cancer early detection test into one of the nation's most widely used electronic health record (EHR) platforms, supporting broader adoption across health systems in the United States.
Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks offer higher risk and potential reward, less tied to economic cycles.
LOS ANGELES--(BUSINESS WIRE)---- $GRAL--GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm.
Partnership expands access to breakthrough blood-based cancer screening intoSuperpower's comprehensive health check and personalized plans. SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the first all-in-one proactive health platform, announced a strategic partnership with GRAIL, Inc. (Nasdaq: GRAL) to bring members access to the Galleri® multi-cancer early detection (MCED) test.
Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, April 1, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.
Investors are hoping follow-up trial data will validate Grail's Galleri test. The failure to meet a trial's primary endpoint could be due to how the trial was designed rather than the efficacy of the Galleri test.
Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 25, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.
One Fin Capital sold 380,000 shares of GRAIL in the fourth quarter. The quarter-end position value declined by $22.47 million as a result of the sale.
The probability that the company will receive FDA approval and insurance coverage for its Galleri test might justify buying the stock at current levels. Management hopes folllow up data from its three-year trial of Galleri
When Richard the Lionheart led crusades to the Middle East they were funded by crippling taxes at home. President Donald Trump's war in Iran could well hit regular Americans' pockets and draw the same ire from markets.
Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time NEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on GRAL are encouraged to submit their information now.
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) have received a consensus recommendation of "Hold" from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the
Cancer test maker Grail said on Thursday that chief executive Bob Ragusa will retire effective June 1, and the company's president, Josh Ofman, will take over the helm.
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026.
The company's three-year trial of Galleri in England failed to meet its primary endpoint. Management hopes that follow-up data will better demonstrate the efficacy of its test.
